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Abstract: The UMMS Wellstone Program is a foundation and NIH-funded cooperative 
research center focusing on identifying biomarkers for facioscapulohumeral muscular 
dystrophy (FSHD) to gain insight into the molecular pathology of the disease and to 
develop potential therapies. FSHD is characterized by progressive wasting of skeletal 
muscles, with weakness often initiating in facial muscles and muscles supporting the 
scapula and upper arms. While the genetics associated with FSHD are complex, the 
major form of the disease, FSHD1, is linked to contraction of the D4Z4 repeat region 
located at chromosome 4q. Recently, a transcript encoded at the distal end of the repeat 
region, Dux4-fl, normally expressed in embryonic stem cells and germ cells, was also 
detected in differentiated muscle cells and biopsies from FSHD subjects, giving rise to 
the hypothesis that DUX4-FL function contributes to muscle weakness.  
 We established a repository of high quality, well-characterized primary and 
immortalized muscle cell strains from FSHD and control subjects in affected families to 
provide biomaterials for cell and molecular studies to the FSHD research community. 
qPCR and immunostaining analyses demonstrate similar growth and differentiation 
characteristics in cells from FSHD and control subjects within families. We detected 
Dux4-fl transcript and protein in FSHD cells as recently described; interestingly, we also 
detected Dux4-fl in muscle cells from a subset of control individuals, suggesting that any 
Dux4-fl-mediated myopathy would require additional modifying elements. Microarray 
analysis of FSHD and control muscle cells demonstrated that several genes were 
upregulated in FSHD cells, including genes that were concurrently identified as 
downstream targets of Dux4-fl and as candidate FSHD disease genes. Future studies 
will further characterize the RNA and protein expression of candidate disease genes in 
cells from FSHD and control subjects, including nonmanifesting subjects with the D4Z4 
lesion but no muscle weakness, and utilizing whole transcriptome sequencing (RNAseq) 
to identify additional candidates. 
